ciprofloxacin has been researched along with Canine Diseases in 26 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Orbifloxacin tablets were administered orally to 23 dogs with superficial and/or deep staphylococcal pyoderma." | 7.73 | Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs. ( Miller, WH; Peters, J; Scott, DW, 2006) |
| "Plasma and skin concentrations of orbifloxacin (Orbax tablets, Schering-Plough Animal Health) were assessed in 14 clinically normal dogs and 14 dogs with pyoderma following oral administration of the drug at 7." | 7.71 | Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. ( Katz, T; Kay-Mugford, PA; Ngoh, M; Simmons, R; Varma, KJ; Weingarten, AJ; White, A; Zolynas, R, 2002) |
| "Treatment with enrofloxacin would not be recommended for a bacterial organism intermediate or resistant in susceptibility to enrofloxacin since appropriate levels of enrofloxacin would not be attained." | 6.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| "Ciprofloxacin was administered intravenously @5 mg/kg body weight to six healthy dogs." | 5.35 | Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ( Akhtar, M; Anwar, MI; Arshed, MJ; Muhammad, F, 2009) |
| "Ciprofloxacin generic tablets approved for human use frequently are administered to dogs for treatment of bacterial infections because they are inexpensive and readily available." | 3.85 | Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ( Papich, MG, 2017) |
| "Orbifloxacin tablets were administered orally to 23 dogs with superficial and/or deep staphylococcal pyoderma." | 3.73 | Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs. ( Miller, WH; Peters, J; Scott, DW, 2006) |
| "Plasma and skin concentrations of orbifloxacin (Orbax tablets, Schering-Plough Animal Health) were assessed in 14 clinically normal dogs and 14 dogs with pyoderma following oral administration of the drug at 7." | 3.71 | Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. ( Katz, T; Kay-Mugford, PA; Ngoh, M; Simmons, R; Varma, KJ; Weingarten, AJ; White, A; Zolynas, R, 2002) |
| "Treatment with enrofloxacin would not be recommended for a bacterial organism intermediate or resistant in susceptibility to enrofloxacin since appropriate levels of enrofloxacin would not be attained." | 2.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| "Incidence of ciprofloxacin-resistant Campylobacter infections among humans has increased over the last several years." | 1.51 | Ciprofloxacin resistance among Campylobacter jejuni isolates obtained from shelter dogs in Texas. ( Cummings, KJ; LaLonde-Paul, D; Lawhon, SD; Rodriguez-Rivera, LD; Wu, J, 2019) |
| "Ciprofloxacin was administered intravenously @5 mg/kg body weight to six healthy dogs." | 1.35 | Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs. ( Akhtar, M; Anwar, MI; Arshed, MJ; Muhammad, F, 2009) |
| "Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213)." | 1.32 | In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. ( Etoré, F; Ganière, JP; Médaille, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Tumpa, A | 1 |
| Štritof, Z | 1 |
| Pintarić, S | 1 |
| Qekwana, DN | 1 |
| Oguttu, JW | 1 |
| Sithole, F | 1 |
| Odoi, A | 1 |
| Papich, MG | 3 |
| LaLonde-Paul, D | 1 |
| Cummings, KJ | 1 |
| Rodriguez-Rivera, LD | 1 |
| Wu, J | 1 |
| Lawhon, SD | 1 |
| Marshall, KR | 1 |
| Walton, SA | 1 |
| Boyd, M | 1 |
| Bishop, B | 1 |
| Wellehan, J | 1 |
| Craft, W | 1 |
| Santoro, D | 1 |
| Shimizu, T | 2 |
| Harada, K | 2 |
| Kataoka, Y | 1 |
| Daniels, JB | 1 |
| Tracy, G | 1 |
| Irom, SJ | 1 |
| Lakritz, J | 1 |
| Liu, X | 1 |
| Lazzaroni, C | 1 |
| Aly, SA | 1 |
| Thungrat, K | 1 |
| Boothe, DM | 1 |
| Domosławska, A | 1 |
| Zduńczyk, S | 1 |
| Jurczak, A | 1 |
| Janowski, T | 1 |
| Cole, LK | 2 |
| Kwochka, KW | 2 |
| Hillier, A | 2 |
| Smeak, DD | 2 |
| Lehman, AM | 1 |
| Muhammad, F | 1 |
| Akhtar, M | 1 |
| Anwar, MI | 1 |
| Arshed, MJ | 1 |
| Escobar, C | 1 |
| Grindem, CB | 1 |
| Govendir, M | 1 |
| Norris, JM | 1 |
| Hansen, T | 1 |
| Wigney, DI | 1 |
| Muscatello, G | 1 |
| Trott, DJ | 1 |
| Malik, R | 1 |
| Gebru, E | 1 |
| Damte, D | 1 |
| Choi, MJ | 1 |
| Lee, SJ | 1 |
| Kim, YH | 1 |
| Park, SC | 1 |
| Haenni, M | 1 |
| Ponsin, C | 1 |
| Métayer, V | 1 |
| Médaille, C | 2 |
| Madec, JY | 1 |
| Kay-Mugford, PA | 1 |
| Weingarten, AJ | 1 |
| Ngoh, M | 1 |
| Zolynas, R | 1 |
| White, A | 1 |
| Katz, T | 1 |
| Simmons, R | 1 |
| Varma, KJ | 1 |
| Ganière, JP | 1 |
| Etoré, F | 1 |
| Kowalski, JJ | 1 |
| Kelbick, NT | 1 |
| Scott, DW | 1 |
| Peters, J | 1 |
| Miller, WH | 1 |
| Lin, AE | 1 |
| Davies, JE | 1 |
| Court, EA | 1 |
| Watson, AD | 1 |
| Martin, P | 1 |
| Riddle, C | 1 |
| Lemons, CL | 1 |
| Altier, C | 1 |
| van den Hoven, R | 1 |
| Wagenaar, JA | 1 |
| Walker, RD | 1 |
| Irwin, PJ | 1 |
| Whithear, K | 1 |
| Lavelle, RB | 1 |
| Parry, BW | 1 |
| Lautzenhiser, SJ | 1 |
| Fialkowski, JP | 1 |
| Bjorling, D | 1 |
| Rosin, E | 1 |
2 trials available for ciprofloxacin and Canine Diseases
| Article | Year |
|---|---|
Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
Topics: Animals; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Dog Diseases; Dogs; Dose-Response Re | 2009 |
Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Enrofloxacin; Female; Fluoroquino | 2006 |
24 other studies available for ciprofloxacin and Canine Diseases
| Article | Year |
|---|---|
Prevalence and antimicrobial susceptibility of Enterococcus spp. from urine of dogs and cats in northwestern Croatia.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cat Diseases; Cats; Chloramphenic | 2022 |
Patterns and predictors of antimicrobial resistance among Staphylococcus spp. from canine clinical cases presented at a veterinary academic hospital in South Africa.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clinda | 2017 |
Ciprofloxacin Pharmacokinetics in Clinical Canine Patients.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Female; Hal | 2017 |
Ciprofloxacin resistance among Campylobacter jejuni isolates obtained from shelter dogs in Texas.
Topics: Animals; Campylobacter Infections; Campylobacter jejuni; Ciprofloxacin; Cross-Sectional Studies; Dog | 2019 |
Erysipeloid lesions caused by Erysipelothrix rhusiopathiae in a dog: clinical and histopathological findings, molecular diagnosis and treatment.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Ciprofloxacin; Dog Di | 2019 |
Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Drug Resist | 2013 |
Fluoroquinolone levels in healthy dog urine following a 20-mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against Escherichia coli isolated from canine urinary tract infections.
Topics: Animals; Antineoplastic Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Enrof | 2014 |
In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type I; Dog Diseases; | 2014 |
Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxac | 2017 |
Stenotrophomonas maltophilia isolated from prostatic fluid as an infertility factor in a male dog.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dog Diseases; Dogs; Gram-Negative Bacterial Infection | 2017 |
Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs.
Topics: Animals; Anti-Infective Agents; Body Temperature; Chromatography, High Pressure Liquid; Ciprofloxaci | 2009 |
What is your diagnosis? Urine crystals in a dog.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Crystallization; Dog Diseases; Dogs; Male | 2010 |
Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Ciprofloxacin; Dog Diseases; Dogs; Enrofloxacin; | 2011 |
Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Base Sequence; Ciprofloxacin; Dog Diseases; Dogs; | 2012 |
Veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing Klebsiella pneumoniae ST15 clone.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cat Diseases; Cats; Ciprofloxacin; Cross Infection; | 2012 |
Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Case-Control Studies; Chromatography, High Pre | 2002 |
In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Micro | 2004 |
Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dog Diseases; Dogs; Female; Male; Pyoderma; Staphyloc | 2006 |
Occurrence of highly fluoroquinolone-resistant and methicillin-resistant Staphylococcus aureus in domestic animals.
Topics: Animals; Animals, Domestic; Anti-Infective Agents; Cat Diseases; Cats; Chickens; Ciprofloxacin; Comm | 2007 |
Pseudomonas aeruginosa bacteraemia in a dog.
Topics: Animals; Bacteremia; Ciprofloxacin; Dog Diseases; Dogs; Male; Microbiological Techniques; Pseudomona | 1994 |
Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; E | 2000 |
In vitro activity of difloxacin against canine bacterial isolates.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Dose-Response Relationship, Drug; | 2000 |
Acute bronchopneumonia associated with Mycobacterium fortuitum infection in a dog.
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchopneumonia; Ciprofloxacin; Dog Diseases; Dogs; | 2000 |
In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Combinations; Drug Synergism | 2001 |